此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Therapeutic Writing to Reduce Stress (RESeT)

2022年9月12日 更新者:University of North Carolina, Chapel Hill

Writing to Reduce Stress in Expectant Moms: The RESet Study

Purpose: The investigators hypothesize that exposure to chronic environmental stress is a risk factor for adverse pregnancy outcomes related to preterm birth and preeclampsia among high-risk pregnant women. Additionally, the investigators hypothesize that women can be screened for high levels of environmental stress through the perceived stress scale, and therapeutic writing can be used as a low-resource intervention to help decrease maternal perceived stress and inflammation - measured through analysis of maternal serum and placental samples.

Participants: Pregnant women at high risk for adverse pregnancy outcomes, including pre-eclampsia and preterm birth, enrolled in prenatal care at UNC will be recruited for participation

Procedures: Using results from the perceived stress scale, the investigators will identify women who screen positive for high environmental stress. Women meeting inclusion criteria will be contacted for possible participation at regularly scheduled prenatal visits. Women who are enrolled will be randomized to generalized writing prompts, therapeutic writing prompts, or no writing during their pregnancy to be administered at each prenatal visit. Maternal blood sample for biochemical markers of stress and gene expression will be obtained at the initial visit; a followup blood sample will be obtained later in pregnancy, and a small portion of the placenta saved at delivery. Delivery outcomes will be obtained through medical record review.

研究概览

地位

主动,不招人

详细说明

During pregnancy, women regularly interact with healthcare professionals, an often untapped resource and opportune time to optimize mental health, positively impacting outcomes. Cumulative psychosocial stress is a risk factor for several adverse obstetric outcomes including preterm birth (PTB), preeclampsia, fetal growth restriction, and postpartum depression.

The overarching hypothesis of this study is that pregnant women with high levels of stress can be identified through easily-implemented screening tools; importantly, the investigators propose that these women can be engaged in care via a cost-effective therapeutic writing intervention combined with the availability of expert pastoral and perinatal psychiatry resources.

Women will be enrolled early in pregnancy and followed prospectively. Some women (if randomized to a writing group) will complete a standardized writing prompt at several time points during gestation. The investigators will follow their outcomes prospectively.

研究类型

介入性

注册 (实际的)

15

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • North Carolina
      • Chapel Hill、North Carolina、美国、27599
        • University of North Carolina Women's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 50年 (成人)

接受健康志愿者

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Women will be prospectively recruited.

    1. Gestational age: All women presenting for prenatal care at 8.0 to 19.9 weeks' gestation through the UNC-Hospitals High Risk obstetrics clinic will be screened for high risk of an adverse pregnancy outcome (ex: preterm birth or pre-eclampsia) through review of their medical record.
    2. Singleton viable intrauterine pregnancy, with dating confirmed by ultrasound or plans for ultrasound to confirm dating prior to study enrollment
    3. No structural abnormalities or aneuploidy
    4. Ability to communicate in and provide consent in English
    5. Women with at least ONE of the following high risk criteria:

      a. Short cervix by endovaginal ultrasound, measuring <25mm b. Prior spontaneous preterm birth 16.0 - 33.9 weeks' gestation i. Documentation of the prior spontaneous preterm birth in the patient's medical records is desirable but is not required for eligibility.

      ii. The previous preterm delivery cannot be an antepartum stillbirth but an intrapartum stillbirth (due to extreme prematurity) is allowable.

      c. Chronic hypertension on medications d. History of pre-eclampsia requiring delivery <37 weeks' gestation, or history of severe pre-eclampsia delivering at any gestational age

      OR

    6. Women with at least TWO of the following moderate risk criteria:

      1. Prior preterm birth 34.0-36.9 weeks
      2. Chronic hypertension not requiring medications
      3. History of term pre-eclampsia
      4. Type II diabetes on insulin
      5. Obesity with a BMI >30
      6. Smoking during pregnancy
      7. Black race
      8. Maternal age <18 years old or >40 years old
      9. Nulliparous
      10. Uninsured, or medicaid insurance
    7. Women who meet at least one major or 2 minor inclusion criteria along with the other criteria above will then be screened for high levels of acute and chronic stress and trauma using the Perceived Stress questionnaire to determine final eligibility for the study

Exclusion Criteria:

  1. Persistent Illicit drug or alcohol abuse during current pregnancy >12 weeks. Use of tobacco and/or marijuana is not an exclusion. Methadone or suboxone use in an approved treatment program is not an exclusion.
  2. Prior preterm birth or preeclampsia was in a pregnancy complicated by fetal aneuploidy or major congenital fetal anomalies in the absence of another pregnancy meeting above inclusion criteria
  3. Major congenital anomaly such as major structural deficit of the heart, lungs, or brain or aneuploidy

    1. Mild renal abnormalities, clubfoot, isolated cleft lip/palate, etc. in the fetus are not a reason for exclusion
    2. For a detailed list of major anomalies, see Table 3 - Major Fetal Anomalies / Congenital Malformations, below. Two or more minor anomalies observed together (see Table 2 - Minor Fetal Anomalies / Congenital Malformations) count as a "major" anomaly
    3. Isolated 'soft markers' for aneuploidy (such as choroid plexus cysts, echogenic bowel, etc.) are not a reason for exclusion
    4. If aneuploidy screening is performed, any aneuploidy screen positive test with a risk for aneuploidy greater than 1 in 25 without negative confirmatory definitive aneuploidy testing is reason for exclusion
  4. Spanish speaking women
  5. Women participating in other intervention-based studies

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Therapeutic Writing Prompts
Participants will be given writing prompts that discuss events that have been perceived as stressful in their lives and how they may or may not have cultivated resilience and coping strategies because of it.
Participants will be given journals with writing prompts to be completed throughout their pregnancy.
安慰剂比较:General Writing Prompts
Participants will be given writing prompts that discuss "neutral" topics unrelated to their life stress, resilience, or coping.
Participants will be given journals with writing prompts to be completed throughout their pregnancy.
无干预:No Writing
Participants will not be given writing prompts during their prenatal care. They will be given blank journals that will NOT contain any instructions or writing prompts.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percent Participation in Writing Activity
大体时间:through study completion, an average of 7 months per participant and 2 years for entire study
The percentage of women who respond that they completed their assigned writing activity will be measured.
through study completion, an average of 7 months per participant and 2 years for entire study
Statistically significant improvement (reduction) in the Perceived Stress Scale Score
大体时间:through study completion, an average of 7 months per participant and 2 years for entire study
Psychological instrument used to measure one's perception of stress (score range 0-40) will be assessed before and after the assigned writing activity. Higher scores on the scale indicate a higher vulnerability for those with a high levels of perceived stress in their life. Prior studies have noted the average score for a female age 30-44 is approximately 14.
through study completion, an average of 7 months per participant and 2 years for entire study
Proportion of women with adverse perinatal outcomes
大体时间:outcome will be ascertained at delivery
We will define adverse pregnancy outcomes as a composite of preterm birth <37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups
outcome will be ascertained at delivery
Change in pro-inflammatory biomarkers in maternal blood by randomization group
大体时间:through study completion, an average of 7 months per participant and 2 years for entire study
All women participating in the study will have a blood draw. Levels of stress biomarkers (e.g., interleukin-6) will be compared by randomization group
through study completion, an average of 7 months per participant and 2 years for entire study
Change in pro-inflammatory biomarkers in maternal blood by outcome
大体时间:through study completion, an average of 7 months per participant and 2 years for entire study
All women participating in the study will have a blood draw. Levels of stress biomarkers (e.g., interleukin-6) will be compared between women who develop the adverse perinatal outcome and those who do not
through study completion, an average of 7 months per participant and 2 years for entire study
Change in stress-related gene expression in maternal blood by randomization group
大体时间:through study completion, an average of 7 months per participant and 2 years for entire study
All women participating in the study will have a blood draw. We will evaluate gene expression of the CTRA gene panel (conserved transcriptional response to adversity gene panel) by randomization group
through study completion, an average of 7 months per participant and 2 years for entire study
Change in stress-related gene expression in maternal blood by outcome
大体时间:through study completion, an average of 7 months per participant and 2 years for entire study
All women participating in the study will have a blood draw. We will evaluate gene expression of the CTRA gene panel (conserved transcriptional response to adversity gene panel) by whether or not the patient developed the adverse perinatal outcome
through study completion, an average of 7 months per participant and 2 years for entire study

次要结果测量

结果测量
措施说明
大体时间
Utilization of professional psychiatric care
大体时间:through study completion, an average of 7 months per participant and 2 years for entire study
proportion of women who initiate or continue therapy with professional psychiatric care provider
through study completion, an average of 7 months per participant and 2 years for entire study
Stress related pathways gene expression - placental tissue - by randomization group
大体时间:through study completion, an average of 7 months per participant and 2 years for entire study
After delivery, we will evaluate whether there are differences in the conserved transcriptional response to adversity gene panel (CTRA gene panel) by randomization groups
through study completion, an average of 7 months per participant and 2 years for entire study
Stress related pathways gene expression - placental tissue - by diagnosis of adverse perinatal outcome
大体时间:through study completion, an average of 7 months per participant and 2 years for entire study
After delivery, we will evaluate whether there are differences in the conserved transcriptional response to adversity gene panel (CTRA gene panel) by whether or not the patient developed the adverse perinatal outcome
through study completion, an average of 7 months per participant and 2 years for entire study
Rate of preterm birth less than 37 weeks' gestation by randomization group
大体时间:through study completion, an average of 7 months per participant and 2 years for entire study
we will individually evaluate the outcomes of preterm birth <37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups
through study completion, an average of 7 months per participant and 2 years for entire study
Rate of diagnosis of intrauterine growth restriction, using sex-specific curves, by randomization group
大体时间:through study completion, an average of 7 months per participant and 2 years for entire study
we will individually evaluate the outcomes of preterm birth <37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups
through study completion, an average of 7 months per participant and 2 years for entire study
Rate of diagnosis of preeclampsia by randomization group
大体时间:through study completion, an average of 7 months per participant and 2 years for entire study
we will individually evaluate the outcomes of preterm birth <37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups
through study completion, an average of 7 months per participant and 2 years for entire study
Rate of diagnosis of placental abruption by randomization group
大体时间:through study completion, an average of 7 months per participant and 2 years for entire study
we will individually evaluate the outcomes of preterm birth <37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups
through study completion, an average of 7 months per participant and 2 years for entire study

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Tracy A Manuck, MD、University of North Carolina

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年10月22日

初级完成 (预期的)

2024年12月22日

研究完成 (预期的)

2024年12月22日

研究注册日期

首次提交

2019年4月3日

首先提交符合 QC 标准的

2019年4月4日

首次发布 (实际的)

2019年4月5日

研究记录更新

最后更新发布 (实际的)

2022年9月14日

上次提交的符合 QC 标准的更新

2022年9月12日

最后验证

2022年9月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 18-2187

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

IPD 计划说明

All information that is collected for this study will be stored in locked filing cabinets and/or offices and on the secure UNC server on the RedCap database. Participants will be assigned a unique study-id number for this study. Only the PI and Sponsor for the study will have access to the key linking this study id number to their personal clinical information and identifiers.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

在美国制造并从美国出口的产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅